Novo Nordisk offering its GLP-1 drug Wegovy at huge discount

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Wed, Mar 5, 2025, 8:55 AM

Novo Nordisk (NVO) is now offering its GLP-1 weight-loss drug Wegovy direct to consumers at over half its price, amounting to $499 per month. Yahoo Finance senior health reporter Anjalee Khemlani comes on Market Domination to break down the latest news surrounding the pharmaceutical giant's position in the obesity drug space.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

This post was written and updated by Luke Carberry Mogan.